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Abstract
Background: Angiogenesis is the target of several agents in the treatment of malignancies, including renal cell carcinoma
(RCC). There is a real need for surrogate biomarkers that can predict selection of patients who may benefit from
antiangiogenic therapies, prediction of disease outcome and which may improve the knowledge regarding mechanism of
action of these treatments. Tyrosine kinase inhibitors (TKI) have proven efficacy in metastatic RCC (mRCC). However, the
molecular mechanisms underlying the clinical response to these drugs remain unclear.
Methodology/Principal Findings: The present study aimed to identify molecular biomarkers associated with the response
to sunitinib, a Tyrosine kinase inhibitor. To evaluate this relationship, primary tumors from 23 metastatic RCC patients
treated by sunitinib were analyzed for a panel of 16 biomarkers involved in tumor pathways targeted by sunitinib, using
real-time quantitative reverse-transcriptase PCR. Nine of the 23 patients (39%) responded to sunitinib. Among transcripts
analyzed, only the levels of vascular endothelial growth factor (VEGF) soluble isoforms (VEGF121 and VEGF165) were
associated with the response to sunitinib (P=0.04 for both). Furthermore, the ratio of VEGF soluble isoforms (VEGF121/
VEGF165) was significantly associated with prognosis (P=0.02).
Conclusions: This preliminary study provides a promising tool that might help in the management of metastatic RCC, and
could be extended to other tumors treated by TKI.
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Introduction
Renal cell carcinoma (RCC) represents 5% of malignancies with
38,000 new cases diagnosed in 2006 in the United States [1].
During last decades, this incidence has constantly increased. At the
time of diagnosis, about 30% of RCC are metastatic. A genomic
deletion, involving the von Hippel Lindau (VHL) gene is common
in clear-cell RCCs, which represents 75% of RCCs. Both alleles of
the VHL suppressor gene are inactivated either by deletion,
mutation, or promoter hypermethylation [2].The alteration of
VHL leads to an anarchic stimulation of hypoxic response due to a
dysregulation of a subunits of hypoxia inducible factor (HIF). The
stimulation of HIF results in a dysregulation of HIF target genes,
mainly those encoding for the vascular endothelial growth factor
(VEGF), its receptors (VEGFR), the platelet-derived growth factor
(PDGF) and the urokinase-type plasminogen activator (uPA) with
consequences on angiogenesis and invasion [3]. Angiogenesis plays
an important role in the invasion and dissemination of RCC, and
is mediated by numerous factors. Among pro-angiogenic factors,
VEGF is the mainstay of this process [3,4]. VEGF has five main
isoforms produced by alternative splicing of a gene located on
6p21.3: VEGF121, VEGF165, VEGF189, VEGF145, and VEGF206,
which differ in their bioavailability [5].
Among new concepts developed to improve the management of
metastatic RCC (mRCC), molecules targeting the VEGF have
been developed, especially tyrosine kinase inhibitors (TKI). In first-
line therapy, sunitinib significantly improved progression-free
survival by reducing the risk of relapse by 58% compared with
interferon-a [6]. To date, no predictive biological factors of
response have been identified allowing a better selection of RCC
patients for sunitinib therapy. The present study aimed to identify
biomarkers associated with sunitinib response. To evaluate this
relationship, primary tumors from 23 clear-cell metastatic RCC
patients treated by sunitinib were analyzed retrospectively for the
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targeted by sunitinib.
Results and Discussion
Primary tumors from 23 metastatic RCC patients treated by
sunitinib were analyzed for the gene expression of a panel of 16
biomarkers involved in tumor pathways targeted by sunitinib,
using real-time quantitative reverse-transcriptase PCR (qRT-
PCR). A correlation between their expression and the response
to sunitinib was then evaluated.
According to RECIST criteria [6,7], overall objective response
to sunitinib was achieved in 18 patients. Partial response (PR) was
observed in 9 patients and response of stable disease (SD) $3
months were observed in 9 patients. No complete response was
observed. The median duration of follow-up was 26.6 months.
Soluble VEGF isoforms, VEGF121 and VEGF165, were
significantly associated with the response to sunitinib at three
months (Figure 1). Indeed, the tumor transcript levels were
significantly higher in responding (RP and SD) patients compared
with patients who had a failure to treatment. The median values
were respectively: for VEGF121 PR: 1222; SD: 425; Failure: 241
(p=0.04), and for VEGF165 PR: 905; SD: 460; Failure: 352
(p=0.04). For tumors overexpressing VEGF121 and VEGF165, the
probability of response was 81% and 90%, respectively.
The immunohistochemical study of total VEGF protein (using a
human-anti-VEGF antibody R&D, France) showed a significant
correlation between tumor response and difference in VEGF
expression between tumor center and margins (p=0.015). Indeed,
the higher was this difference, the better was the response
(Figure 2). No significant correlation was found between mRNA
levels of VEGFR-1, VEGFR-2 and PDGF-Receptors (targeted by
sunitinib), and response to sunitinib.
The response to sunitinib was independent from tumor size and
noteworthy, from the prognostic group and was not significantly
associated with Fuhrman grade. Furthermore, the overall survival
of patients with a VEGF121/VEGF165 ratio lower than 1.25 (ratio
cut-off value determined from the third quartile) was significantly
higher than those of patients with a ratio higher than 1.25
(p=0.02; median survival time, 25.2 months versus not reached).
Indeed, as evaluated by a Cox proportional cause specific hazards
model, the estimated hazard ratio (HR) for the risk of death since
diagnosis in the group with high values of VEGF121/VEGF165
ratio was 5.8 (95 percent confidence interval: 1.4 to 24.5; p=0.02)
(Figure 3).
Transcript levels for VEGF121 and VEGF165 were significantly
higher for the subset of patients with Fuhrman grade 1 or TNM
stage 1 tumors (p=0.05; p=0.04 and p=0.003; p=0.002
respectively). When considering treatment effect, sunitinib partial
response was found to decrease the incidence rate by 50% though
this was not significant. (HR: 0.50, 95% CI: 0.10 to 2.50, p=0.40)
and by 73% for stable disease (HR: 0.27, 95% CI: 0.04 to 1.63,
p=0.15). The ratio remained non significant when considering
pooled data (failure versus PR and SD). The estimated hazard
ratio in the partial response and stable disease group is 0.37 (95%
CI: 0.09 to 1.59; p=0.18).
To date, no predictive factor or biomarker of the response to
sunitinib has been identified in mRCC. Moreover, there are no
clinical factors that can discriminate and/or predict a preferential
efficacy of TKIs compared with mTOR inhibitor or bevacizumab.
Some trends were observed such as slight differences according to
age [8], and histological subtypes [9]. The occurrence of arterial
hypertension has been evoked as a predictive factor of response to
sunitinib [10]. In terms of biomarkers, patients with either high or
low baseline plasma VEGF benefit from treatment in terms of
progression-free survival in a large cohort of mRCC treated with
sorafenib [11]. In another study, Fold increase in plasma VEGF
after two cycles of sunitinib treatment in clear cell-RCC was
shown to be significantly lower in patients that obtained clinical
benefit as compared to patients that progressed [12]. This
biomarker measurement allows therefore the stratification of
patients in respect to response only after two cycles of treatment.
In a series of five mRCC patients, the free-plasma VEGF has also
been found to be a possible pharmacodynamic marker for
bevacizumab antiangiogenic activity [13]. It has been also
demonstrated that sunitinib inhibits signaling pathways involved
in bevacizumab resistance in mRCC patients, and that baseline
levels of soluble VEGFR-3 and VEGF-C may have a potential
utility as biomarkers of clinical efficacy in this setting [14]. These
findings support the potential significance of the VEGF/VEGFR-
2 pathway predominant in mRCC. In spite of the inhibition of
VEGFR-2 by sunitinib, the magnitude of its role in vivo is not fully
clarified. Clinically, patients who have high levels of VEGF soluble
isoforms achieve a better response to sunitinib. Thereby, the
VEGF/VEGFR pathway could be the preferential target of
sunitinib. Our results favored the hypothesis that response to
therapy is associated with the inhibition of VEGF pathway,
depending on the inhibition of VEGF signal. This is likely due to
the inhibition of both angiogenesis and cell proliferation driven by
the presence of a VEGF/VEGFR-2 autocrine loop in tumor cells.
Indeed, RCC tumor cells, producing high levels of VEGF121 and
VEGF165, display a higher ability to grow and to invade the
extracellular matrix [15,16]. Based on these observations, further
researche confirming clinical significance and underlying biologic
mechanisms are warranted.
Figure 1. Boxplot of four RNA expression levels (in log10 scale)
according to treatment response. The expression levels of
interesting transcripts were normalized to the housekeeping PPIA
(peptidylprolyl isomerase A) and TBP (TATA-box binding protein) gene
transcripts. Since there was no difference between control genes,
results were presented as copies of target gene per copy of PPIA. The
median values and their corresponding logarithmic values in brackets
were respectively: for VEGF121 PR 1222 (7.1), SD 425 (6.0) and Failure 241
(5.4); and for VEGF165 PR 905 (6.8), SD 460 (6.1) and Failure 352 (5.8).
(*) for p,0.05.
doi:10.1371/journal.pone.0010715.g001
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prognostic for progression-free and overall survivals in RCC [11].
Patients with higher tumor VEGF121 mRNA levels have a
significantly shorter survival compared with those having lower
levels suggesting that angiogenic activity might be up-regulated in
tumors with a high ability to invade [17,18]. Thereby, patients
with high soluble VEGF levels might have a more aggressive
disease, and the improved outcome observed in our series might
be a reflection of disease biology.
It is hard to speculate at this point on why the association of
survival is better with the ratio of VEGF121/VEGF165 than with
VEGF121 alone. However, we have previously shown that
VEGF121 is the most expressed isoform in RCC [17]. Tomisawa
et al have also shown that VEGF121 is more expressed than
VEGF165 and VEGF189 and while all the analyzed RCC primary
tumors expressed VEGF121, only 70% showed expression of
VEGF165. In addition, these authors report that neither VEGF165
nor VEGF189 were expressed alone in RCCs [16]. It is worth
noting that this ratio avoids the use of housekeeping genes and
would thus provide a more easy to use clinical test.
Therefore, if these new drugs provide considerable promise for
patients, there is a crucial need for a better selection of patients.
Indeed, tumors with close characteristics can present opposite
behavior with either important and long regressions, or very short-
term progressions. TKI are multikinase inhibitors, which impact a
wide cascade of signaling pathways. Thereby, the optimization of
their efficiency is based on a correlation between response to
treatment and individual tumor signatures.
In conclusion, this preliminary study constitutes a first step in
the identification of surrogate biomarkers of sunitinib antiangio-
genic activity in mRCC and requires confirmation in a larger
independent series of patients. Indeed, tumor soluble VEGF
mRNA represents a potentially promising tool that might help the
clinician to identify patients who are likely to benefit from sunitinib
and avoid a costly and potentially toxic administration of this
treatment in non-responding patients.
Materials and Methods
Patients
We analyzed retrospectively data from 23 consecutive patients
with clear-cell mRCC, and treated in a single institution (Ho ˆpital
Henri Mondor, Cre ´teil, France) with sunitinib (delivered orally at
a dose of 50 mg/day for 4 weeks, every 6 weeks) after failure of a
first-line therapy with interferon-a. The study was performed in
accordance with the precepts established by the Helsinki
Declaration and approved by Ho ˆpital Henri Mondor Ethic
Committee; patients were enrolled after giving written consent.
All data were analyzed anonymously. Patients’ characteristics are
summarized in Table 1.
Tumor response was assessed according to the Response
Evaluation Criteria in Solid Tumor (RECIST) after three months
of sunitinib treatment [6,7].
Biomarkers Evaluation
A panel of 16 biomarkers involved in angiogenesis and invasion
pathways was assessed. The transcript panel included VEGF
(isoforms 121, 165, and 189), and their receptors (VEGFR-1 and
R-2); PDGF-A and -B and their receptors (PDGF-Ra and -Rb);
fibroblast growth factor (FGF)-2; HIF-1a; chemokine receptor 4
(CXCR4); uPA, its receptor (uPA-R) and inhibitor plasminogen
activator inhibitor-1 (PAI-1); and lymphatic vessel endothelial
Figure 2. Immunohistochemical staining of total VEGF protein in sections of human RCC tissues. Representative RCC tumor center (left)
and margins (right) with lower and strong expression of VEGF respectively.
doi:10.1371/journal.pone.0010715.g002
Figure 3. Kaplan-Meier survival curve according to the ratio
VEGF121/VEGF165.
doi:10.1371/journal.pone.0010715.g003
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receptor.
Samples from primary tumors of clear-cell RCC not containing
necrosis were selected and the different biomarker analyses were
performed on adjacent sections.
Total RNA was extracted from frozen tumors using TRIzol
(Invitrogen). cDNA was synthesized using High-Capacity cDNA
Kit (Applied-Biosystems). Transcript levels were measured in each
tumor by quantitative RT-PCR using Perfect-Master Mix-Probe
(AnyGenes, France) on LightCycler (Roche, France). The expres-
sion levels of interesting transcripts were normalized to the
housekeeping PPIA (peptidylprolyl isomerase A) and TBP
(TATA-box binding protein) gene transcripts. Since there was no
difference between control genes, results were presented as copies of
target gene per copy of PPIA. Gene set assays were designed using
Primer-Express Software (Applied-Biosystems) and primers and
probes sequences were available upon request. Gene expression
levels were determined using standard calibration curves prepared
from gene-specific PCR products. All PCRs were done in duplicate.
Immunohistochemical analyses were carried out using antibod-
ies directed against VEGF (Abcam), VEGF-R1, VEGF-R2 (R&D
Systems), and PDGF-Rb (Cell Signaling). Tissue sections were
incubated overnight with the specified primary antibody, and then
incubated with the appropriate biotinylated secondary antibodies.
Peroxidase reactivity was visualized using 3-amino-9-ethylcarba-
zole (AEC, DAKO).
Statistical Analysis
Variables analyzed were according to the Memorial Sloan-
Kettering Cancer Center (MSKCC) risk model, Fuhrman grade,
and treatment response at three months. Gene expression levels
were presented in log10 scale. Mann-Whitney or Kruskal-Wallis
tests were used. Survival curves were estimated by the Kaplan-
Meier method, and compared using a log-rank test. The
characteristics associated with the risk of dying were tested using
a Cox proportional cause-specific hazards model. The association
between biomarkers and the risk of dying was reported as the
hazard ratio (HR) together with its 95% confidence interval
(95%CI). All tests and p-value were two-sided, and differences
were considered as significant for p,0.05. Statistical analysis was
performed using the Open Source R software (R 2.4.0).
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